Pfizer Chinese JV partner gets FDA warning letter; AZ teams up with feds on antibiotic development;

@FiercePharma: ViroVet spins out of Aratana with focus on livestock health. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: BMS' Opdivo guns for kidney cancer nod with FDA 'breakthrough' tag. Article | Follow @CarlyHFierce

> The Chinese half of a Pfizer ($PFE) joint venture has found itself crosswise with the FDA, which has banned products from one of its plants. Report

> AstraZeneca ($AZN) signed up with the Department of Health and Human Services to develop antibiotics for use against bioterrorism agents and drug-resistant infections. Report

> A gay man taking Gilead Sciences' ($GILD) Truvada as an HIV-prevention tool says Mutual of Omaha discriminated against him when it turned him down for long-term care insurance. Report

> Hayman Capital's Kyle Bass continues to maintain that his Coalition for Affordable Drugs is only challenging the "worst" drug patents. Report

> Some blood pressure drugs may increase the risk of colorectal polyps, a new study found. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Pentax backs $8M+ round for electrosurgery startup Creo. Article | Follow @FierceMedDev

@EmilyWFierce: Report: Cancer drug spending fuels large increases in Medicare discount drug program. ICYMI from FiercePharma | Follow @EmilyWFierce

> Mobile health apps top 165K mark, with 300 clinical trials using them. More

> Zoll buys an Israeli wearable cardiac monitor maker for $35M. Article

> FDA beefs up testing for duodenoscope cleaning devices. Report

Biotech News

@FierceBiotech: Aerie skyrockets on a mixed success in second PhIII glaucoma study. Article | Follow @FierceBiotech

@JohnCFierce: First on Fierce: OrbiMed sets its sights on a $950M blockbuster biotech fund. News | Follow @JohnCFierce

> A player in J&J's hep C cocktail helps hustle a quick cure. Story

> FDA: Those worries about Addyi and alcohol? We can handle it. More

> Lehmann leaves GSK to head up immuno-oncology at Celyad. Article

Vaccines News

> Takeda joins consortium that accelerates R&D for malaria, TB vaccines. Item

> Vaxent and PREVENT kick off Strep A vaccine trials. More

> Emory team to look at GSK vax response as part of NIH research. Report

> FDA panel recommends Fluad, possibly the first U.S. boosted flu jab. Story

> J&J's Janssen strikes four-year, $28.5M government partnership to advance Ebola vaccine. Article

CRO News

> PRA adding 150 jobs amid Pennsylvania expansion push. Report

> Chiltern closes its Theorem buy, doubling its workforce. Item

> Accelovance inks a nonprofit partnership for melanoma trials. Article

> WuXi brings its genomic heft to Chinese patients with hospital pact. Story

> Evotec upsizes its 2015 projections after a string of partnering deals. Article

Pharma Manufacturing News

> Pfizer Chinese JV partner Zhejiang Hisun Pharma gets FDA warning letter. More

> Nexvet picks up biologics plant in Ireland. Item

> FDA castigates Indian drugmaker over mess at API plant. Report

> Hamburg's pick in line to take over as FDA commissioner. Story

> FDA sears maker of GolfersSkin Sunscreen in warning letter. Article

Pharma Asia News

> Taiwan's TWi Pharmaceuticals raises $87M via GDR in weak pricing. Report

> China's Yabao Pharmaceutical adds to a summer string of tie-ups. Item

> Dual-listed Benitec adds fourth site for hep C trials of TT-034. More

> Low-cost genomic sequencing on the slate for China with Veritas landing? Story

> India's Glenmark says breast cancer candidate GBR 1302 moving to PhI. Article

And Finally... The fake drug industry is exploding, and enforcement is challenging. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.